Management of hepatitis C post-liver transplantation: A comprehensive review

Journal of Clinical and Translational Hepatology

Volumn 3, Issue 2, 2015, Pages 140-148

  Mitchell, Oscar ^a   Gurakar, Ahmet ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Directly acting antivirals; Hepatitis C; Transplant

Indexed keywords

EID: 84970008775     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2015.00005     Document Type: Review

References (102)

1. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31:1090–1101. doi: 10. 1111/j.1478-3231.2011.02494.x.
2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271–278. doi: 10.7326/0003-4819-156-4-201202210-00004.
3. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002;35:266–269.
4. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004;10:886–897.
5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529–538.
6. Kim WR, Smith JM, Skeans MA, Schladt DP, Schnitzler MA, Edwards EB, et al. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant 2014;14:69– 96. doi: 10.1111/ajt.12581.
7. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hep-atology 2013;57:2164–2170. doi: 10.1002/hep.26218.
8. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology 2014;59:1246–1249. doi: 10.1002/hep. 27039.
9. http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf, accessed February 2015.
10. http://www.hcvguidelines.org/, accessed February 2015.
11. Pelletier SJ, Raymond DP, Crabtree TD, Berg CL, Iezzoni JC, Hahn YS, et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplan-tation elevated viral replication rate. Hepatology 2000;32:418–426. doi:10. 1053/jhep.2000.9408.
12. Herrmann E, Zeuzem S, Sarrazin C, Hinrichsen H, Benhamou Y, Manns MP, et al. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antivir Ther 2006;11:371–376.
13. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815–820. doi: 10.1056/NEJM199603283341302.
14. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9:S28–S34. doi:10.1053/jlts. 2003.50248.
15. Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005;11:479–89. doi:10. 3748/wjg.v21.i2.408.
16. Wiesner RH, Sorrell M, Villamil F. International Liver Transplantation Society Expert, Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1–S9.doi:10.1053/jlts.2003.50268.
17. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619–625.
18. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852–858. doi:10.1053/jhep. 2000.17924.
19. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673–684. doi:10.1016/S0168-8278(00)80231-7.
20. Berenguer M, Rayon JM, Prieto M, Aguilera V, Nicolas D, Ortiz V, et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001;7:790–796. doi:10/S1527646501670618.
21. Graziadei IW, Zoller HM, Schloegl A, Nachbaur K, Pfeiffer KP, Mark W, et al. Early viral load and recipient interleukin-28B rs12979860 genotype are pre-dictors of the progression of hepatitis C after liver transplantation. Liver Transpl 2012;18:671–679. doi: 10.1002/lt.23402.
22. Pelletier SJ, Schaubel DE, Punch DJ, Wolfe RA, Port FK, Merion RM. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 2005; 11:434–440. doi:10.1002/lt.20342.
23. Ghabril M, Dickson R, Wiesner R. Improving outcomes of liver retransplanta-tion: an analysis of trends and the impact of Hepatitis C infection. Am J Transplant 2008;8:404–411. doi: 10.1111/j.1600-6143.2007.02082.x.
24. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayon JM, Benlloch S, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006;12:762–767. doi:10.1002/lt.20655.
25. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008;14:S36–S44. doi: 10.1002/lt.21646.
26. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823–830. doi:10.1002/hep.510280333.
27. Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006;43: 492–499. doi:10.1002/hep.21090.
28. Nagai S, Yoshida A, Kohno K, Altshuler D, Nakamura M, Brown KA, et al. Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation. Hepatology 2014;59: 35–45. doi: 10.1002/hep.26536.
29. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011;53:317–324. doi: 10.1002/hep. 24074.
30. Cisneros E, Banos I, Citores MJ, Duca A, Salas C, Noblejas A, et al. Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. Transplantation 2012;94: 275–280.
31. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889–896.
32. Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Camma C, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007;13:733–740. doi:10.1002/lt. 21093.
33. Layden JE, Cotler S, Brown KA, Lucey MR, Te HS, Eswaran S, et al. Racial differences in fibrosis progression after HCV-related liver transplantation. Transplantation 2012;94:178–184. doi: 10.1097/TP.0b013e318253f7fa.
34. Verna EC, Valadao R, Farrand E, Pichardo EM, Lai JC, Terrault NA, et al. Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver Transpl 2012;18:461– 467. doi: 10.1002/lt.23376.
35. Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64:721–726.
36. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8: 362–369.
37. Bosch W, Heckman MG, Pungpapong S, Diehl NN, Shalev JA, Hellinger WC. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation 2012;93:723–728. doi: 10. 1097/TP.0b013e3182472876.
38. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002;2:461–466.
39. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51: 248–252. doi:10.1136/gut.51.2.248.
40. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202–210.
41. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003;9:S44–S47.
42. Briceno J, Ciria R, Pleguezuelo M, de la Mata M, Muntane J, Naranjo A, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009;15:37– 48. doi: 10.1002/lt.21566.
43. Subramanian V, Seetharam AB, Vachharajani N, Tiriveedhi V, Angaswamy N, Ramachandran S, et al. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation 2011;92:1259–1268. doi: 10.1097/TP.0b013e318235a1ab.
44. Baron PW, Sindram D, Higdon D, Howell DN, Gottfried MR, Tuttle-Newhall JE, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000; 6:407–412.
45. Terrault NA, Stravitz RT, Lok AS, Everson GT, Brown RS, Kulik LM, et al. Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology 2014;59:1311– 1319. doi: 10.1002/hep.26920.
46. Papatheodoridis GV, Davies S, Dhillon AP, Teixeira R, Goulis J, Davidson B, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001;72:412–418.
47. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayon JM, Benlloch S, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosup-pression. J Hepatol 2006;44:717–722.
48. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclo-sporin versus tacrolimus as primary immunosuppressant after liver trans-plantation: a meta-analysis. Am J Transplant 2006;6:1578–1585. doi: 10. 1111/j.1600-6143.2006.01360.x.
49. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004;10:1258–1262.
50. Levy G, Grazi GL, Sanjuan F, Wu Y, Muhlbacher F, Samuel D, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients. (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus Liver Transpl 2006;12:1464–1472. doi: 10.1002/lt.20802.
51. Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, Lopez-Andujar R, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010;90:1204–1209. doi: 10.1097/TP.0b013e3181fa93fa.
52. Liu Z, Chen Y, Tao R, Xv J, Meng J, Yong X. Tacrolimus-based versus cyclo-sporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review. PLoS One 2014;9:e107057. doi: 10.1371/journal.pone.0107057.
53. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004;77:226–231.
54. Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, et al. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007;47:793–798. doi: 10.1016/j.jhep.2007.07. 023.
55. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003;9:S90–S94. doi:10.1053/jlts.2003.50247.
56. Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389–396. doi: 10.1016/S0168-8278(03)00310-6.
57. Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, et al. Sofos-buvir and ribavirin prevent recurrence of HCV infection after liver transplan-tation: an open-label study. Gastroenterology 2015;148:100–107.e1. doi: 10.1053/j.gastro.2014.09.023.
58. Testa G, Goldstein RM, Netto G, Abbasoglu O, Brooks BK, Levy MF, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation 1998;65:925–929.
59. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384–393. discussion 393-394.
60. Marroquin CE, Marino G, Kuo PC, Plotkin JS, Rustgi VK, Lu AD, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl 2001; 7:762–768. doi:10/S1527646501360768.
61. Ballarin R, Cucchetti A, Spaggiari M, Montalti R, Di Benedetto F, Nadalin S, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation 2011;91:1265–1272. doi: 10.1097/TP. 0b013e318219eb8f.
62. Ofosu A, Durand C, Alqahtani S, Cameron A, Sulkowski M, Gurakar A. Implications of Treating Hepatitis C Virus Infection in Individuals Awaiting Liver Transplantation. Am J Gastroenterol 2014;109:S162.
63. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008;8:2426–2433. doi: 10.1111/j.1600-6143.2008.02362.x.
64. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642– 650. doi: 10.1053/gast.2003.50095.
65. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274–287. doi: 10.1016/j.jhep.2008.05.002.
66. Guillouche P, Feray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011;33:163– 174. doi: 10.1111/j.1365-2036.2010.04505.x.
67. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005;5:118–124. doi:10.1111/j.1600-6143.2004.00648.x.
68. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, et al. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavir-in as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011;17:528–538. doi: 10.1002/lt.22271.
69. Burton JR Jr, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014;61:508–514. doi: 10. 1016/j.jhep.2014.04.037.
70. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014;60:78–86. doi: 10.1016/j.jhep.2013.08.018.
71. Saab S, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, et al. Boceprevir in liver transplant recipients. Liver Int 2015;35:192–197. doi: 10.1111/liv. 12548.
72. Verna EC, Saxena V, Burton JR Jr, O'Leary JG, Dodge JL, Stravitz RT, et al. Telaprevir-and Boceprevir-Based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation 2015.
73. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013;19:690–700. doi: 10.1002/lt.23669.
74. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20–27. doi: 10.1002/hep.24443.
75. Coilly A, Furlan V, Roche B, Barau C, Noel C, Bonhomme-Faivre L, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012;56:5728–5734. doi: 10.1128/AAC.01151-12.
76. Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, et al. Phar-macokinetic interaction between the hepatitis C virus protease inhibitor bo-ceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012;56:1622–1630. doi: 10.1002/hep.25831.
77. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Konigsrainer A, Malek NP, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012;18:1464–1470. doi: 10.1002/lt.23542.
78. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatol-ogy 2014;59:46–48. doi: 10.1002/hep.26730.
79. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection. (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384:403–413. doi: 10.1016/S0140-6736(14)60494-3.
80. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection. (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414–426. doi: 10.1016/S0140-6736(14)60538-9.
81. Tanaka T, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Aoki T, et al. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. J Hepatobiliary Pancreat Sci 2015;22:144–150. doi: 10. 1002/jhbp.171.
82. www.olysio.com, accessed February 2015.
83. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology 2014;Dec 29. doi: 10. 1002/hep.27681.
84. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofos-buvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015;148:108–117. doi: 10.1053/j.gastro.2014.10.001.
85. Borentain P, Colson P, Dhiver C, Gregoire E, Hardwigsen J, Danielle B-f, et al. Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in HIV-HCV coinfected patient. Antivir Ther 2014;Aug 8. doi: 10.3851/IMP2841.
86. Kim B, Trivedi A, Thung SN, Grewal P. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver trans-plantation. Semin Liver Dis 2014;34:108–112. doi: 10.1055/s-0034-1371084.
87. Delabaudiere C, Lavayssiere L, Dorr G, Muscari F, Danjoux M, Sallusto F, et al. Successful treatment of fibrosing cholestatic hepatitis with pegylated inter-feron, ribavirin and sofosbuvir after a combined kidney-liver transplantation. Transpl Int 2015;28:255–258. doi: 10.1111/tri.12428.
88. Mathias A, Cornpropst M, Clemons D, Denning J, Symonds WT. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers (Abstract 1869), in 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2012, Boston.
89. www.clinicaltrials.gov, accessed February 2015.
90. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corre-gidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pe-gylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756–1765. doi: 10.1016/S0140-6736 (14)61036-9.
91. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, et al. Multi-center experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015. doi: 10. 1002/hep.27770.
92. ClinicalTrials.gov. An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (GALAXY), accessed February 2015.
93. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211–221. doi: 10. 1056/NEJMoa1306218.
94. Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014;46:923–927. doi: 10.1016/j.dld.2014.06.004.
95. ClinicalTrials.gov. Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Subjects and Subjects Post-liver Transplant (ALLY 1), accessed February 2015.
96. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370: 1889–1898. doi: 10.1056/NEJMoa1402454.
97. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledi-pasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–1493. doi: 10.1056/NEJMoa1316366.
98. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–1888. doi: 10.1056/NEJMoa1402355.
99. Wiles D, Pockros PJ, Zhu Y, Yang JC, Pang PS, McHutchison J, et al. Retreat-ment of Patients Who Failed Prior Sofosbuvir-Based Regimens With All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir Plus Ribavirin for 12 Weeks, in 65th Annual Meeting of the American Association for the Study of Liver Diseases. 2014, Boston.
100. Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T, et al. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Post-Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study, in 65th Meeting of the American Association for the Study of Liver Diseases. 2014, Boston.
101. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, et al. An inter-feron-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371:2375–2382. doi: 10.1056/NEJMoa1408921.
102. www.rxabbvie.com, accessed February 2015.